Article
Author(s):
San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.
Exploring the Effects of Masks on Skin Physiology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 3
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Which Tax Treatment Is Best for Your Dermatology Practice?
Facing Challenges in Pediatric Plaque Psoriasis